Abstract THU0217 – Table 1. Efficacy responses and percentage of patients experiencing AEs ($\geq 5\%$ in any subgroup) at Wk 24

	Primary failure			Secondary failure		
	Placebo (n=75)	Sarilumab 150 mg q2w (n=72)	Sarilumab 200 mg q2w (n=64)	Placebo (n=99)	Sarilumab 150 mg q2w (n=91)	Sarilumab 200 mg q2w (n=103)
Efficacy parameters						
ACR20/50/70,% Responders	33.3/18.7/12.0	51.4/37.5/23.6	51.6/37.5/15.6	35.4/ 18.2/4.0	59.3/39.6/19.8	66.0/41.7/15.5
CDAI, LS mean Δ from baseline (SE)	-15.28 (1.9)	-23.73 (1.9)	-22.73 (2.0)	-17.89 (1.6)	-24.42 (1.6)	-27.43 (1.5)
TEAEs (%)						
Neutropenia	1.3	12.5	10.9	0.0	13.2	12.6
UTI	6.7	1.4	7.8	7.1	5.5	6.8
Increased ALT	1.3	5.6	7.8	0.0	1.1	3.9
uRTI	5.3	1.4	4.7	2.0	3.3	2.9
Hypertriglyceridemia	1.3	8.3	6.3	2.0	3.3	1.0
Accidental overdose	4.0	1.4	6.3	2.0	6.6	2.9
Hypertension	0.0	0.0	6.3	4.0	1.1	2.9
Hypercholesterolemia	0.0	5.6	4.7	0.0	2.2	1.0
Diarrhoea	5.3	0.0	4.7	2.0	1.1	1.9
RA	4.0	0.0	0.0	5.1	3.3	2.9
Injection site erythema	0.0	4.2	4.7	0.0	7.7	1.9
Nasopharyngitis	4.0	4.2	1.6	5.1	7.7	4.9

THU0218

THE EFFICACY AND DRUG SURVIVAL OF THE BIOSIMILAR INFlixIMAB (CT-P13) COMPARED TO THE ORIGINAL REFERENCE INFlixIMAB IN INFLAMMATORY RHEUMATIC DISEASES; RESULTS FROM THE TURKBIO REGISTRY

S. Uslu¹, G. Can¹, S. Senel², E. Dalkilic³, N. Inanc⁴, S. Aka⁵, S.B. Kocaer¹, M. Birlik¹, S. Capar⁶, N. Akkoc⁷, F. Onen¹. ¹Rheumatology, Dokuz Eylul University, Izmir; ²Rheumatology, Erciyes University, Kayseri; ³Rheumatology, Uludag University, Bursa; ⁴Rheumatology, Marmara University, Istanbul; ⁵Rheumatology, Katip Celebi University; ⁶Department of Statistics, Dokuz Eylul University; ⁷Rheumatology, Private Doctor, Izmir, Turkey

Background: Biosimilar infliximab (CT-P13) has been used to treat patients with rheumatoid arthritis (RA), ankylosing spondylitis (AS) and psoriatic arthritis (PsA) in Turkey since 2013.

Objectives: The aim of this study was to examine its efficacy, drug survival and compare it to the original reference infliximab (inf) in patients with inflammatory rheumatic diseases based on the database from the TURKBIO registry.

Methods: All patients with RA, SpA, PsA, and other diseases receiving CT-P13 and inf registered in the TURKBIO database between the dates of June 2013 and January 2017 were included in the study. Demographic information, laboratory parameters and disease indices were collected (at baseline, and months 6 and 12). We used Kaplan Meier survival curves to examine drug survival patterns.

Results: Data collected from a total number of 614 patients were analysed (table 1). The analysis of each treatment group was made according to gender, age, and diagnosis. In both groups most of the patients were diagnosed as having axial SpA, followed by RA, PsA and other diseases. CT-P13 group had female predominance. In patients with RA and PsA, baseline DAS28 scores were found to be higher in CT-P13 group. Baseline values of ASDAS-CRP in SpA patients and CRP in all patients were similar for both groups (table 2). Mean CRP levels at month 6 and ASDAS scores at month 12 were found to be higher in inf group. The ratio of males was higher in axial SpA patients receiving inf, but did not statistically affect the 12th month ASDAS results. The results of the database analysis showed that the drug survival rate of CT-P13(78,4%) is higher than inf(63,6%) at year 4 (figure 1). At 4 year follow-up, drug withdrawal was observed in both groups due to ineffectiveness (CT P13;n=13 54,16%, inf;n=89 41,58%) and side effects (CT-P13;n=8 33,33%, inf;n=43 20,09%). In CT-P13 group, six patients had switched from inf to biosimilar and other 20 had used ≥ 1 previous biologicals. Of the 503 patients who used inf, 164 had used ≥ 1 biologicals previously.

Abstract THU0218 – Table 1. Baseline characteristics of CT-P13 and original infliximab, by diagnostic group

	CT-P13 (n=111)	infliximab (n=503)	P value
Age, mean	44.37	45.68	0.350
F, n%	74 (65.49)	241 (47.25)	<0.001
RA, n%	17 (15.32)	54 (10.74)	0.229
F, n%	14 (82)	44 (81)	1.000
AS+NraxSpa, n%	8 (72.07)	334 (66.40)	0.297
F, n%	50 (63)	140 (42)	0.001
PsA, n%	7 (6.31)	39 (7.75)	0.745
F, n%	4 (57)	25 (64)	1.000
Other, n%	7 (6.31)	76 (15.11)	0.021
F, n%	4 (57)	29 (38)	0.563

Abstract THU0218 – Table 2. Disease activity follow-up

	CT-P13	infliximab	P value
DAS28, mean	3.95	3.47	0.007
Baseline	2.54	2.27	0.385
Month 6	2.18	2.17	0.959
Month 12			
CRP, (mg/L)	21.00	21.82	0.818
Baseline	4.06	13.09	<0.001
Month 6	10.52	9.97	0.889
Month 12			
ASDAS, mean	3.47	3.31	0.280
Baseline	1.57	1.90	0.093
Month 6	1.23	1.87	0.008
Month 12

Abstract THU0218 – Figure 1. Kaplan–Meier survival curve of biosimilar infliximab and original reference infliximab (p<0.05)

Conclusions: The results of this study demonstrated long term higher drug survival rate of biosimilar CT-P13. The study also suggested that efficacy of CT-P13 on disease activity was similar to original infliximab in patients with inflammatory rheumatic diseases.

Disclosure of Interest: None declared

DOI: 10.1136/annrheumdis-2018-eular.6440